Hilde Langseth

Hilde Langseth started at the Norwegian Cancer Registry in 1994 as a researcher and has since become head of the section for molecular epidemiology and infections. Since 2007, she has also managed the Janus serum bank. Hilde has a doctorate in cancer epidemiology from the medical faculty at the University of Oslo from 2007 where she defended her thesis "Risk of cancer and non-malignant mortality among women in the Norwegian Pulp and Paper industry: A focus on ovarian cancer and exposure to asbestos and other dust". Hilde leads a number of studies on cancer biomarkers where epidemiological data is used together with biomarker data derived from biobanks and in recent years has particularly focused on investigating RNA molecules as risk markers and early markers for cancer. Hilde has a number of other positions such as Chief Editor of a journal, member of several committees and councils and as supervisor of PhD and post-doc candidates.

 

Hilde Langseth is a researcher and head of the Section for Molecular Epidemiology and Infections. She has been head of the Janus serum bank since 2007. She has been employed at the Research Department of the Cancer Registry of Norway since 1994, where she studies the importance of profession and environmental exposure in cancer development.  

Hilde leads a number of studies of cancer biomarkers where epidemiological data are used together with biomarker data derived from biobanks. The aim is to identify risk markers and markers that can detect cancer at an early stage.

In recent years, her research has been particularly focused on investigating RNA molecules as risk markers and early markers for cancer in pre-diagnostic serum samples from the Janus serum bank.

Since 2019, Hilde has been Honorary Senior Research Officer at Imperial College London, Department of Epidemiology and Biostatistics, where she was a researcher guest in 2018-2019.

She is Chief Editor of the journal Frontiers in Public Health, Life-Course Epidemiology and Social Inequalities in Health.

Since 2010 she has been a member of the Biobank and Registry Committee at Oslo University Hospital, and a member of the National Quality Registry for Gynecological Cancer since 2020.

Hilde also works in several international cancer consortia.

Langseth is a Cand. scient in biology from NTNU in Trondheim, specializing in pulmonary physiology and epidemiology.

She completed her PhD in cancer epidemiology at the Faculty of Medicine at the University of Oslo in 2007 with the thesis: 'Risk of cancer and non-malignant mortality among women in the Norwegian Pulp and Paper industry: A focus on ovarian cancer and exposure to asbestos and other dust'.

In 2016, she took research management training at the University of Oslo, and she supervises postdoc and PhD students.

Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Lang PhD W, Jacobs EJ, Mucci LA, Platz EA, Cook MB; Prostate Cancer Cohort Consortium (PC3) Working Group. Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. J Natl Cancer Inst. 2021 Jun 1;113(6):727-734. doi: 10.1093/jnci/djaa154. Erratum in: J Natl Cancer Inst. 2022 Jan 07;: PMID: 33010161; PMCID: PMC8248961.

Xie SH, Ness-Jensen E, Langseth H, Gislefoss RE, Mattsson F, Lagergren J. Prediagnostic circulating levels of sex hormones and survival in esophageal adenocarcinoma. Int J Cancer. 2021 Feb 15;148(4):905-913. doi: 10.1002/ijc.33285. Epub 2020 Sep 22. PMID: 32895915; PMCID: PMC7820945.

Chen D, Grimsrud TK, Langseth H, Barr DB, Bassig BA, Blair A, Cantor KP, Gammon MD, Lan Q, Rothman N, Engel LS. Prediagnostic serum concentrations of organochlorine pesticides and non-Hodgkin lymphoma: A nested case-control study in the Norwegian Janus Serum Bank Cohort. Environ Res. 2020 Aug;187:109515. doi: 10.1016/j.envres.2020.109515. Epub 2020 Apr 29. PMID: 32445944; PMCID: PMC9278122.

Irvin SR, Weiderpass E, Stanczyk FZ, Brinton LA, Trabert B, Langseth H, Wentzensen N. Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank. Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):636-642. doi: 10.1158/1055-9965.EPI-19-0675. Epub 2020 Jan 13. PMID: 31932414; PMCID: PMC7060092.

Rounge TB, Umu SU, Keller A, Meese E, Ursin G, Tretli S, Lyle R, Langseth H. Circulating small non-coding RNAs associated with age, sex, smoking, body mass and physical activity. Sci Rep. 2018 Dec 5;8(1):17650. doi: 10.1038/s41598-018-35974-4. PMID: 30518766; PMCID: PMC6281647.

Abu-Halima M, Keller A, Becker LS, Fischer U, Engel A, Ludwig N, Kern F, Rounge TB, Langseth H, Meese E, Keller V. Dynamic and static circulating cancer microRNA biomarkers - a validation study. RNA Biol. 2023 Jan;20(1):1-9. doi: 10.1080/15476286.2022.2154470. PMID: 36511578; PMCID: PMC9754110.

Hjerkind KV, Gislefoss RE, Tretli S, Nystad W, Bjørge T, Engeland A, Meyer HE, Holvik K, Ursin G, Langseth H. Cohort Profile Update: The Janus Serum Bank Cohort in Norway. Int J Epidemiol. 2017 Aug 1;46(4):1101-1102f. doi: 10.1093/ije/dyw302. PMID: 28087783.

Langseth H, Gislefoss RE, Martinsen JI, Dillner J, Ursin G. Cohort Profile: The Janus Serum Bank Cohort in Norway. Int J Epidemiol. 2017 Apr 1;46(2):403-404g. doi: 10.1093/ije/dyw027. PMID: 27063606.